50-35-1 (+/-)-Thalidomide AKSci F010
 
 
Loading Please Wait...
  F010    
(+/-)-Thalidomide
, 98% (HPLC)
 
Thalomid
(+/-)-2-(2,6-Dioxo-3-piperidinyl)-1H-isoindole-1,3(2H)-dione




IDENTITY
CAS Number:50-35-1
MDL Number:MFCD00153873
MF:C13H10N2O4
MW:258.23
EINECS:200-031-1
SPECIFICATIONS & PROPERTIES
Purity:98% (HPLC)
Spectra:NMR, HPLC
Physical Form:White to off-white crystalline powder
Melting Point:269-276°C
Long-Term Storage:Store at room temperature
UN #:UN2811
Hazard Class:6.1
Packing Group:III

BIOLOGICAL INFO
Application(s):Angiogenesis Inhibitor; Immunosuppressive Agent; Leprostatic Agent; Teratogen
Form:Free Base

REVIEW

 Thalidomide is used for treating multiple myeloma in combination with dexamethasone, erythema nodosum leprosum, and alleviating symptoms of HIV, with strict controls to prevent birth defects. Thalidomide is a potent inhibitor of new blood vessel growth (angiogenesis), which is required for tumor growth.

REFERENCES
[1]Bejanyan N, Tiu RV, Raza A, Jankowska A, Kalaycio M, Advani A, Chan J, Saunthararajah Y, Mooney L, Maciejewski JP, Sekeres MA (2012). A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer. 118(16):3968-76. PMID 22180010.
[2] Horton MR, Hallowell RW (2012). Revisiting thalidomide: fighting with caution against idiopathic pulmonary fibrosis. Drugs Today (Barc). 48(10):661-71. PMID 23110262.

GHS

Pictograms

Signal Word
Danger

Hazard Statements
H301; H312; H361

Precautionary Statements
P201; P202; P264; P270; P280; P301+P310; P302+P352; P308+P313; P322; P330; P363; P405; P501


Current as of June 24, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > Immunomodulators


PubChem